Search Results

Fruquintinib 5 mg  | Purity Not Available

TargetMol

Fruquintinib is an orally available, small molecule inhibitor of vascular endothelial growth factor receptors (VEGFRs), with potential anti-angiogenic and antineoplastic activities.

More Information Supplier Page

Fruquintinib 50 mg  | Purity Not Available

TargetMol

Fruquintinib is an orally available, small molecule inhibitor of vascular endothelial growth factor receptors (VEGFRs), with potential anti-angiogenic and antineoplastic activities.

More Information Supplier Page

Fruquintinib 10 mg  | Purity Not Available

TargetMol

Fruquintinib is an orally available, small molecule inhibitor of vascular endothelial growth factor receptors (VEGFRs), with potential anti-angiogenic and antineoplastic activities.

More Information Supplier Page

Fruquintinib 100 mg  | Purity Not Available

TargetMol

Fruquintinib is an orally available, small molecule inhibitor of vascular endothelial growth factor receptors (VEGFRs), with potential anti-angiogenic and antineoplastic activities.

More Information Supplier Page

PIK-75 10 mg  | 98.19%

TargetMol

PIK-75, a DNA-PK and PI3K inhibitor, suppresses DNA-PK(IC50=2 nM), p110α(IC50=5.8 nM) and p110γ(IC50=76 nM).

More Information Supplier Page

PIK-75 25 mg  | 98.19%

TargetMol

PIK-75, a DNA-PK and PI3K inhibitor, suppresses DNA-PK(IC50=2 nM), p110α(IC50=5.8 nM) and p110γ(IC50=76 nM).

More Information Supplier Page